Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?

摘要: Pre-eclampsia (P-Ec) is a complex multisystem disorder of unknown aetiology reported to occur in about 6% 8% all pregnancies throughout the world. This disease associated with fibrin deposition and occlusive lesions placental vessels. Pro-thrombin activatable fibrinolysis inhibitor (pro-TAFI) relatively recently described glycoprotein that can be converted into its active form (TAFIa) by thrombin, thrombin-thrombomodulin plasmin. TAFIa potentially inhibits removing C-terminal lysine arginine residues from fibrin. These are required for adsorption tissue-type plasminogen activator (t-PA) Therefore, decreases plasmin formation protects clot against lysis. An increased pro-TAFI/TAFIa levels has been some clinical conditions thrombotic tendency, as type II diabetes mellitus, deep vein thrombosis symptomatic artery disease. Few studies have investigated normal or complicated pregnancy but contrasting results were reported. Understanding role pathogenesis P-Ec hold great promise improving management. In this context, large-scale study evaluating plasma TAFI antigen activity, synthesis metabolism pre-eclamptic women required. Recently new selective inhibitors developed. The design therapy treat and/or prevent P-Ec, based on successful use inhibitors, may significant ramifications.